Arcus Biosciences Aktie
WKN DE: A2JGDZ / ISIN: US03969F1093
|
12.12.2025 18:57:32
|
Arcus Biosciences Shares Drop 12% After Discontinuing Phase 3 STAR-221 Trial
(RTTNews) - Arcus Biosciences, Inc. (RCUS) is trading 11.50 percent lower at $22.25, down $2.89 on Friday, after announcing the discontinuation of its Phase 3 STAR-221 study conducted with Gilead Sciences.
The stock opened at $21.15 and has traded between $20.35 and $24.00 so far on the New York Stock Exchange. The bid sits at $22.54 and the ask at $22.60, with volume at 4,426,823 versus an average of 1,561,846.
Arcus shares are now trading well off their recent peak, within a 52-week range of $6.50 to $26.40.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Arcus Biosciences Inc Registered Shsmehr Nachrichten
|
06.08.25 |
Ausblick: Arcus Biosciences zieht Bilanz zum abgelaufenen Quartal (finanzen.net) |
Analysen zu Arcus Biosciences Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
| Arcus Biosciences Inc Registered Shs | 21,53 | -14,36% |
|